查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971787

抗体药物复合体(ADC) 市场分析及预测至 2035 年：按类型、产品类型、服务、技术、应用、最终用户、製程、阶段、解决方案、模式

Antibody Drug Conjugate Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions, Mode
出版日期: | 出版商: Global Insight Services | 英文 303 Pages | 商品交期: 3-5个工作天内

价格
简介目录

抗体药物复合体（ADC）市场预计将从2024年的210亿美元成长到2034年的439亿美元，复合年增长率约为7.7%。抗体药物复合体（ADC）市场涵盖将单株抗体与细胞毒性药物结合的疗法，这些疗法能够针对特定的癌细胞，同时最大限度地减少对健康组织的损伤。该市场的成长动力主要来自于标靶癌症治疗的进步、癌症发生率的上升以及药物递送系统的技术创新。正在进行的临床试验、监管核准以及主要行业参与者之间的策略联盟也进一步推动了市场成长。

抗体药物复合体(ADC) 市场持续稳定成长，这主要得益于标靶癌症治疗和个人化医疗的进步。肿瘤学领域处于领先地位，其中乳癌和骨髓恶性肿瘤因其巨大的未满足医疗需求而成为重点关注领域。在这些领域中，乳癌ADC 已展现出令人鼓舞的临床疗效，并取得了最大的成功。血液系统恶性肿瘤也呈现类似的成长势头，这得益于其创新的作用机制。连接子技术对于提高 ADC 的稳定性和疗效至关重要。可裂解连接子能够实现药物在肿瘤部位的精准释放，并展现出性能优势。不可裂解连接子也因其更高的治疗指数而备受关注。含有细胞毒性药物（例如奥瑞他汀类和美登素类）的有效载荷因其强大的抗肿瘤活性而具有巨大的增长潜力。拓朴异构酶抑制剂等新兴有效载荷因其提供新的治疗方法而备受关注。策略合作和研发投入正在推动市场成长，促进创新，并拓展 ADC 产品线。

市场区隔
类型 单株抗体、连接子和细胞毒性药物
产品 Adcetris、卡西拉、恩赫兹、特罗德尔维、波利维
服务 契约製造、合约研究和临床试验服务
科技 可切割连接子、不可切割连接子、位点特异性连接
适应症 乳癌、淋巴瘤、白血病、肺癌、摄护腺癌、卵巢癌
最终用户 医院、专科诊所、研究机构、製药公司
过程 研发、製造、品管
步 药物发现、临床前研究、临床研究、商业化
解决方案 客製化抗体开发、抗体工程、连接子开发
给药途径 静脉注射和皮下注射

市场概况：

抗体药物复合体(ADC) 市场正经历着市场份额和定价策略的动态变化。各公司正利用创新的定价模式来提高药物的可及性并促进其广泛应用。新产品的推出至关重要，领先的製药公司正不断推出尖端 ADC 以满足尚未满足的医疗需求。这种竞争格局的特点是策略联盟和伙伴关係关係，旨在拓展治疗产品组合併巩固市场影响。对个人化医疗和标靶治疗的关注正在推动市场成长，北美凭藉其先进的医疗基础设施和强大的研发实力保持着主导地位。 ADC 市场的竞争日益激烈，主要企业正大力投资研发以维持其竞争优势。对行业领先企业的比较分析表明，它们都注重创新和疗效。监管至关重要，ADC 的核准和商业化受到严格的指导方针约束。欧洲药品管理局 (EMA) 和美国食品药物管理局(FDA) 在塑造市场动态发挥关键作用。遵守这些法规是进入和拓展市场的必要条件。随着技术的进步和对精准肿瘤学的日益重视，该市场的未来前景光明。

主要趋势和驱动因素：

抗体药物复合体(ADC) 市场正经历强劲成长，这主要得益于标靶癌症治疗和个人化医疗的进步。关键趋势包括新型连接子和有效载荷的整合，从而提高治疗的疗效和安全性。製药公司正加大研发投入，以创新和拓展其 ADC 产品组合。此外，全球癌症发生率的上升也推动了对更有效治疗方法的需求。监管部门的核准和有利的报销政策进一步促进了市场扩张。全球人口老化也是导致癌症发生率上升的原因之一，进一步推动了市场成长。生技公司与学术机构之间的合作正在加速创新步伐。此外，在非肿瘤领域开发 ADC 的趋势日益明显，拓宽了治疗应用范围。新兴市场医疗基础设施的改善和对先进疗法认知度的提高，为市场带来了许多机会。预计该市场将持续成长。

限制与挑战：

抗体药物复合体（ADC）市场面临许多重大限制与挑战。其中一个关键限制因素是ADC的高昂研发和生产成本，这可能阻碍中小企业进入市场。复杂的生产流程和严格的监管要求加重了企业的财务负担，限制了市场扩张。另一个挑战是缺乏熟悉ADC技术的专业人才。人才短缺会减缓创新和研发，并可能影响市场成长。此外，ADC的复杂性可能引发稳定性和安全性方面的担忧，需要进行广泛的研究和测试以确保疗效和患者安全。同时，竞争格局日益激烈，众多公司争夺市场份额，可能导致价格压力。最后，对个人化医疗解决方案和客製化ADC疗法的需求使大规模生产变得更加复杂，带来了物流和扩充性的挑战。所有这些因素共同限制了ADC市场的成长潜力。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 连接器
    • 细胞毒性物质
  • 市场规模及预测：依产品划分
    • ADCETRIS
    • 门头
    • 恩赫兹
    • 托罗德尔比
    • 聚维
  • 市场规模及预测：依服务划分
    • 契约製造
    • 委託研究
    • 临床试验服务
  • 市场规模及预测：依技术划分
    • 可裂解连接子
    • 不可切割的连接子
    • 位点特异性结合
  • 市场规模及预测：依应用领域划分
    • 乳癌
    • 淋巴瘤
    • 白血病
    • 肺癌
    • 摄护腺癌
    • 卵巢癌
  • 市场规模及预测：依最终用户划分
    • 医院
    • 专科诊所
    • 研究所
    • 製药公司
  • 市场规模及预测：依製程划分
    • 研究与开发
    • 製造业
    • 品管
  • 市场规模及预测：依发展阶段划分
    • 药物发现
    • 临床前阶段
    • 临床
    • 商业化
  • 市场规模及预测：按解决方案划分
    • 客製化抗体开发
    • 抗体工程
    • 连接子开发
  • 市场规模及预测：依管理途径
    • 静脉注射
    • 皮下注射

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Seattle Genetics
  • ImmunoGen
  • Mersana Therapeutics
  • ADC Therapeutics
  • Sutro Biopharma
  • Heidelberg Pharma
  • MabPlex International
  • Concortis Biotherapeutics
  • Abzena
  • NBE-Therapeutics
  • Synthon Biopharmaceuticals
  • Alligator Bioscience
  • Zymeworks
  • AstraZeneca Biologics
  • Avid Bioservices

第九章：关于我们

简介目录
Product Code: GIS33629

Antibody Drug Conjugate Market is anticipated to expand from $21 billion in 2024 to $43.9 billion by 2034, growing at a CAGR of approximately 7.7%. The Antibody Drug Conjugate Market encompasses therapeutics that combine monoclonal antibodies with cytotoxic agents, targeting specific cancer cells while minimizing damage to healthy tissues. This market is driven by advancements in targeted cancer therapies, increasing cancer prevalence, and technological innovations in drug delivery systems. The market's growth is further propelled by ongoing clinical trials, regulatory approvals, and strategic collaborations among key industry players.

The Antibody Drug Conjugate (ADC) Market is experiencing robust expansion, driven by advancements in targeted cancer therapies and personalized medicine. The oncology segment is at the forefront, with breast cancer and hematologic malignancies being primary areas of focus due to high unmet needs. Within this segment, breast cancer ADCs are the top performers, offering promising clinical outcomes. Hematologic ADCs follow closely, capitalizing on innovative mechanisms of action. The linker technology segment is pivotal, enhancing ADC stability and efficacy. Cleavable linkers lead in performance, facilitating precise drug release at tumor sites. Non-cleavable linkers also gain traction, offering improved therapeutic indices. The payload segment, featuring cytotoxic agents like auristatins and maytansinoids, shows significant growth potential, driven by their potent anti-tumor activity. Emerging payloads, such as topoisomerase inhibitors, are gaining attention as they offer novel therapeutic avenues. Strategic collaborations and investments in research and development are propelling market growth, fostering innovation and expanding the ADC pipeline.

Market Segmentation
TypeMonoclonal Antibodies, Linkers, Cytotoxins
ProductAdcetris, Kadcyla, Enhertu, Trodelvy, Polivy
ServicesContract Manufacturing, Contract Research, Clinical Trial Services
TechnologyCleavable Linker, Non-cleavable Linker, Site-specific Conjugation
ApplicationBreast Cancer, Lymphoma, Leukemia, Lung Cancer, Prostate Cancer, Ovarian Cancer
End UserHospitals, Specialty Clinics, Research Institutes, Pharmaceutical Companies
ProcessResearch and Development, Manufacturing, Quality Control
StageDiscovery, Preclinical, Clinical, Commercialization
SolutionsCustom Antibody Development, Antibody Engineering, Linker Development
ModeIntravenous, Subcutaneous

Market Snapshot:

The Antibody Drug Conjugate (ADC) market is experiencing dynamic shifts in market share and pricing strategies. Companies are leveraging innovative pricing models to enhance accessibility and drive adoption. New product launches are pivotal, with pharmaceutical giants introducing cutting-edge ADCs to address unmet medical needs. This competitive landscape is characterized by strategic collaborations and partnerships, aiming to expand therapeutic portfolios and enhance market presence. The focus on personalized medicine and targeted therapies is propelling market growth, with North America maintaining a leadership position due to advanced healthcare infrastructure and robust R&D activities. Competition in the ADC market is intensifying, with key players investing heavily in research and development to maintain a competitive edge. Benchmarking against industry leaders reveals a focus on innovation and efficacy. Regulatory influences are significant, as stringent guidelines govern the approval and commercialization of ADCs. The European Medicines Agency and the U.S. FDA play crucial roles in shaping market dynamics. Compliance with these regulations is essential for market entry and expansion. The market's trajectory is promising, driven by technological advancements and an increasing focus on precision oncology.

Geographical Overview:

The Antibody Drug Conjugate (ADC) market is witnessing robust growth across various regions, each with unique dynamics. North America remains dominant, propelled by advanced healthcare infrastructure and substantial investment in biotechnology research. The region's strong pharmaceutical presence and focus on innovation further bolster its market leadership. Europe follows, with significant investments in healthcare research and a supportive regulatory environment fostering a thriving ADC market. The Asia Pacific region is experiencing rapid expansion, driven by increasing healthcare needs and rising investments in biotechnology. Countries like China and India are emerging as key players, with growing pharmaceutical industries and supportive government policies. Latin America and the Middle East & Africa are promising new growth pockets. In Latin America, the market benefits from rising healthcare expenditure and improved access to advanced therapies, while the Middle East & Africa are recognizing the potential of ADCs in addressing unmet medical needs and enhancing treatment outcomes.

Key Trends and Drivers:

The Antibody Drug Conjugate Market is experiencing robust growth, propelled by advances in targeted cancer therapies and personalized medicine. A key trend is the integration of novel linkers and payloads, enhancing the efficacy and safety of these therapies. Pharmaceutical companies are increasingly investing in research and development to innovate and expand their ADC portfolios. Moreover, the growing prevalence of cancer globally is driving demand for more effective treatment options. Regulatory approvals and favorable reimbursement policies are further facilitating market expansion. The aging global population also contributes to the increasing incidence of cancer, thereby boosting market growth. Collaborations between biotech firms and academic institutions are accelerating the pace of innovation. Additionally, there is a rising trend towards the development of ADCs for non-oncological indications, broadening the scope of therapeutic applications. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of advanced therapies is on the rise. This market is poised for sustained expansion.

Restraints and Challenges:

The Antibody Drug Conjugate (ADC) market is confronted with several significant restraints and challenges. A primary restraint is the high cost of ADC development and production, which can deter smaller companies from entering the market. The complex manufacturing processes and stringent regulatory requirements add to the financial burden, limiting market expansion. Another challenge is the limited availability of skilled professionals with expertise in ADC technology. This scarcity can slow innovation and development, impacting market growth. Additionally, the intricate nature of ADCs can lead to stability and safety concerns, requiring extensive research and testing to ensure efficacy and patient safety. Furthermore, the competitive landscape is intensifying, with numerous players vying for market share, which can lead to pricing pressures. Lastly, the need for personalized medicine solutions and tailored ADC therapies complicates mass production efforts, posing logistical and scalability challenges. These factors collectively restrain the ADC market's growth potential.

Key Players:

Seattle Genetics, ImmunoGen, Mersana Therapeutics, ADC Therapeutics, Sutro Biopharma, Heidelberg Pharma, MabPlex International, Concortis Biotherapeutics, Abzena, NBE-Therapeutics, Synthon Biopharmaceuticals, Alligator Bioscience, Zymeworks, AstraZeneca Biologics, Avid Bioservices

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Linkers
    • 4.1.3 Cytotoxins
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Adcetris
    • 4.2.2 Kadcyla
    • 4.2.3 Enhertu
    • 4.2.4 Trodelvy
    • 4.2.5 Polivy
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Manufacturing
    • 4.3.2 Contract Research
    • 4.3.3 Clinical Trial Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cleavable Linker
    • 4.4.2 Non-cleavable Linker
    • 4.4.3 Site-specific Conjugation
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lymphoma
    • 4.5.3 Leukemia
    • 4.5.4 Lung Cancer
    • 4.5.5 Prostate Cancer
    • 4.5.6 Ovarian Cancer
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Specialty Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Research and Development
    • 4.7.2 Manufacturing
    • 4.7.3 Quality Control
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical
    • 4.8.3 Clinical
    • 4.8.4 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Custom Antibody Development
    • 4.9.2 Antibody Engineering
    • 4.9.3 Linker Development
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Intravenous
    • 4.10.2 Subcutaneous

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Seattle Genetics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ImmunoGen
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Mersana Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 ADC Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sutro Biopharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Heidelberg Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 MabPlex International
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Concortis Biotherapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Abzena
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 NBE-Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Synthon Biopharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Alligator Bioscience
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Zymeworks
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 AstraZeneca Biologics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Avid Bioservices
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us